<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243853</url>
  </required_header>
  <id_info>
    <org_study_id>VER001</org_study_id>
    <nct_id>NCT01243853</nct_id>
  </id_info>
  <brief_title>Alpha-galactosidase Enzyme and Irritable Bowel Syndrome</brief_title>
  <acronym>ALFA</acronym>
  <official_title>Alpha-galactosidase Enzyme and Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verman Oy Ab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verman Oy Ab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether alpha-galactosidase enzyme is affective in
      alleviating the symptoms of irritable bowel syndrome (IBS).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IBS symptom severity</measure>
    <time_frame>baseline</time_frame>
    <description>The IBS symptom severity score (IBS-SSS) questionnaire is used</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IBS symptom severity</measure>
    <time_frame>1 month</time_frame>
    <description>The IBS symptom severity score (IBS-SSS) questionnaire is used</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IBS symptom severity</measure>
    <time_frame>2 months</time_frame>
    <description>The IBS symptom severity score (IBS-SSS) questionnaire is used</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IBS symptom severity</measure>
    <time_frame>3 months</time_frame>
    <description>The IBS symptom severity score (IBS-SSS) questionnaire is used</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IBS symptom severity</measure>
    <time_frame>follow-up (4 months)</time_frame>
    <description>The IBS symptom severity score (IBS-SSS) questionnaire is used</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Alpha-galactosidase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpha-galactosidase</intervention_name>
    <description>3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo</description>
    <arm_group_label>Alpha-galactosidase</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of IBS according to Rome III criteria, additionally abdominal
             distension or flatulence the most disturbing symptom

          -  Age 18-65 years

          -  Colonoscopy conducted within the previous 5 years, finding macroscopically and
             histologically normal

        Exclusion Criteria:

          -  Organic GI disease. Treated (min. 1 year) coeliac disease patients, and subjects with
             known and treated lactose intolerance are allowed to participate

          -  Malignancy

          -  Significant gastrointestinal surgery

          -  Clinically significant aberrancies in the screening-phase laboratory analyses

          -  Changes in regular medication during the previous 4 weeks

          -  Pregnancy or breast feeding

          -  Other disease or state that based on the investigator's evaluation complicates the
             conduction of the intervention, i.e. alcoholism, dementia

          -  Hereditary galactosemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jari Koskenpato, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastrolääkärit Oy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jari Koskenpato, MD, PhD</last_name>
    <phone>+358505702835</phone>
    <email>jari.koskenpato@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastrolääkärit Oy</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jari Koskenpato, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>January 14, 2011</last_update_submitted>
  <last_update_submitted_qc>January 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jari Koskenpato/Principal Investigator</name_title>
    <organization>Gastrolääkärit Oy</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

